TG Therapeutics, Inc.
TGTXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
Ublituximab Phase 3 Est. Readout
Primary completion for Ublituximab trial (NCT05877963) in Relapsing Multiple Sclerosis
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How TGTX's past catalysts played out
Teriflunomide
Relapsing Multiple Sclerosis (RMS)
Ublituximab
Non-Hodgkins Lymphoma
Umbralisib
Marginal Zone Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis (RMS) | - | - |
Ublituximab | Phase 3 | Non-Hodgkins Lymphoma | - | - |
Umbralisib | Phase 2 | Marginal Zone Lymphoma | - | - |
Relapsing Multiple Sclerosis (RMS)
2 drugs in this indication
Marginal Zone Lymphoma
1 drug in this indication
Non-Hodgkins Lymphoma
1 drug in this indication
Relapsing Multiple Sclerosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TG Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in TG Therapeutics, Inc.'s (TGTX) pipeline across Phase 3, Phase 2. Its lead program is Teriflunomide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TG Therapeutics, Inc.'s next FDA catalyst?→
TG Therapeutics, Inc.'s (TGTX) next tracked catalyst is a Phase 3 expected September 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TGTX biotech catalysts?→
Add TGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TG Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.